E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

Biotechnology Market Sector
More Pages: Page: 1 (2) 3 4 5 6 7 8 9 10 11
OTC PK:AVTOAvantogen Oncology, Inc.
 Innovate Oncology acquires, develops and seeks to commercialize novel compounds to treat various types of cancer. Co.'s portfolio of compounds under development consists of three compounds that are being tested to target some of the most common types of cancer. Co.'s business strategy is to develop its existing pharmaceutical products, acquire additional pharmaceutical product candidates predominantly in the oncology sector, selectively license its technology and establish strategic collaborations to advance its product pipeline.
 Market CapDay's VolumeLast TradeChange
 $6M0$0.00330.0%
 
OTC PK:AVXTAVAX Technologies, Inc.
 AVAX Technologies is a development stage biotechnology company specializing in the development and commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. Co.'s vaccine consists of autologous (the patient's own) cancer cells that have been treated with a chemical (?haptenized?) to make them more visible to the patient's immune system. Co.'s previous clinical trials for the AC Vaccine have concentrated on melanoma, ovarian carcinoma and non-small cell lung cancer. Co. also offers biological manufacturing services to other biotechnology and pharmaceutical companies.
 Market CapDay's VolumeLast TradeChange
 $18M786,000$0.0225-13.4616%
 
OTC PK:AVROAverion International Corp.
 Averion International is a contract research organization focused on providing clients with services and applications throughout the drug development process. It has two business segments: clinical research and staffing services. Its clinical research segment offers a suite of clinical trial support services for Phase I through Phase IV clinical trials. Its services include patient and investigator recruitment, biostatistical analysis, data management, data entry and verification and regulatory affairs services. The staffing services segment provides management and regulatory compliance services to pharmaceutical, biotechnology, healthcare and other life science companies.
 Market CapDay's VolumeLast TradeChange
 -0$0.00620.0%
 
NASDAQ:AVGNAVIGEN
 Avigen is a biopharmaceutical company focused on developing and commercializing small molecule therapeutics and biologics to treat serious neurological and neuromuscular disorders. Co. operates in a single segment. Co.'s lead product candidates (AV650 and AV411) primarily address neuromuscular spasm and spasticity and neuropathic pain. In addition, Co. is currently developing AV513, a botanical drug based on a carbohydrate molecule which is extracted from sea algae, as an oral therapy for the treatment of bleeding disorders. Co. also has other candidates in research, including AV333 for neuropathic pain.
 Market CapDay's VolumeLast TradeChange
 -0$1.320.0%
 
OTC PK:BASFYBASF SE American Depositary Shares
 BASF is a chemical company. Co.'s operations are organized into five segments: Chemicals, Plastics, Performance Products, Agricultural Products & Nutrition and Oil & Gas. The Chemicals segment includes organic, basic inorganic and intermediate chemicals. The Plastics segment includes standard plastics and specialty plastics. The Performance Products segment includes new product development, system solutions and application development. The Agricultural Products & Nutrition segment includes active ingredients, fine chemicals and plant biotechnology research. The Oil & Gas segment includes natural gas trading and exploration and production.
 Market CapDay's VolumeLast TradeChange
 $62,537M21,218$60.21-1.4244%
 
OTCBB:BAYWBaywood International, Inc. New -
 Baywood International is a nutraceutical company specializing in the development, marketing and distribution of its own brands under the names Baywood PURECHOICE , Baywood SOLUTIONS , Baywood EVOLUTION? and Complete La Femme . Co. distributes their products through independent and chain health food stores, pharmacies, grocery stores, and other direct-to-consumer channels both internationally and domestically. As of Dec. 31, 2006, Co. had 23 distinct products each of which targets specific needs and conditions of consumers. Co. intends to develop other new products within these lines in the future.
 Market CapDay's VolumeLast TradeChange
 $79M0$0.610.0%
 
OTCBB:BSLMBio Solutions Manufacturing, Inc.
 Bio-Solutions Manufacturing, Inc. is a technology provider of biological solutions to meet the demand of industries seeking environmentally friendly forms of waste bioremediation.
 Market CapDay's VolumeLast TradeChange
 -0$0.00050.0%
 
NASDAQ:BCRXBIOCRYST PHARM
 BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases and viral infections. Co. integrates the necessary disciplines of biology, crystallography, medicinal chemistry and computer modeling to utilize structure-based drug design to discover and develop small molecule pharmaceuticals. As of Dec 31 2006, Co.'s product candidates included Fodosine ?, its transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP) and peramivir, an inhibitor of influenza neuraminidase.
 Market CapDay's VolumeLast TradeChange
 -395,525$5.84-5.5017%
 
NASDAQ:BIIBBIOGEN IDEC
 Biogen Idec is engaged in the development, manufacturing, and commercialization of novel therapies in the areas of oncology, neurology and immunology. Co. has five commercial products: AVONEX , for the treatment of relapsing multiple sclerosis (MS); RITUXAN , for the treatment of relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphomas, or B-cell NHLs; TYSABRI for the treatment of relapsing forms of MS; ZEVALIN , a radioimmunotherapy for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell NHL; and FUMADERM , a immunomudulator for the treatment of severe psoriasis.
 Market CapDay's VolumeLast TradeChange
 -1,959,547$57.16-0.4008%
 
OTCBB:BPURWBiopure Corporation Warrants to Purchase Class A 12/20/2010
 Biopure develops and manufactures oxygen therapeutics, a class of pharmaceuticals that are administered intravenously to transport oxygen to the body's tissues. Co. has developed and manufactures two products: Hemopure (HBOC-201) for human use, approved in South Africa for the treatment of adult surgical patients who are acutely anemic and for the purpose of eliminating, reducing or delaying the need for donated red blood cell transfusions in these patients; and Oxyglobin (HBOC-301) for veterinary use, approved by the U.S. Food and Drug Administration and by the European Commission for the treatment of anemia in dogs. Co.'s registered trademarks include Biopure , Hemopure , and Oxyglobin .
 Market CapDay's VolumeLast TradeChange
 -0$0.010.0%
 
NASDAQ:BPURBIOPURE-A
 Biopure develops and manufactures oxygen therapeutics, a class of pharmaceuticals that are administered intravenously to transport oxygen to the body's tissues. Co. has developed and manufactures two products: Hemopure (HBOC-201) for human use, approved in South Africa for the treatment of adult surgical patients who are acutely anemic and for the purpose of eliminating, reducing or delaying the need for donated red blood cell transfusions in these patients; and Oxyglobin (HBOC-301) for veterinary use, approved by the U.S. Food and Drug Administration and by the European Commission for the treatment of anemia in dogs. Co.'s registered trademarks include Biopure , Hemopure , and Oxyglobin .
 Market CapDay's VolumeLast TradeChange
 -0$0.0750.0%
 
OTC PK:BIOQBIOQUAL, Inc.
 Bioqual supports the National Institutes of Health by providing research services in the following research areas: cancer, AIDS, hepatitis, influenza, immunology, transgenics, contraception, breeding and development of genetically defined animals, and neurobiology and behavior.
 Market CapDay's VolumeLast TradeChange
 -0$8.000.0%
 
NYSE:BTIMBIOTIME
 BioTime is engaged in the research and development of synthetic solutions that can be used as blood plasma volume expanders, blood replacement solutions during hypothermic surgery, and organ preservation solutions. Plasma volume expanders are used to treat blood loss in surgical or trauma patients until blood loss becomes so severe that a transfusion of packed red blood cells or other blood products is required. Co. is also developing a specially formulated hypothermic blood substitute solution that would have a similar function and would be used for the replacement of very large volumes of a patient's blood during cardiac surgery, neurosurgery and other surgeries.
 Market CapDay's VolumeLast TradeChange
 -0$7.73+25.691%
 
OTCBB:KDUSCadus Corporation
 Cadus devoted substantially all of its resources to the development and application of novel yeast-based and other drug discovery technologies. Co. has a wholly owned subsidiary, Cadus Technologies, Inc. (the Subsidiary), which holds all of its patents, patent applications, know how, licenses and drug discovery technologies. As at Dec 31 2006, Co. and its subsidiary have no limited operations, and Co. is seeking to license the Subsidiary's drug discovery technologies, engage in joint ventures that will utilize the Subsidiary's drug discovery technologies and use a portion of their available cash to acquire or invest in companies or income producing assets.
 Market CapDay's VolumeLast TradeChange
 -0$1.500.0%
 
NYSE:CVMCEL-SCI Corp.
 CEL-SCI researches and develops drugs and vaccines. Co.'s product, Multikine , is being developed for the treatment of cancer. Co. has conducted clinical trials on Multikine in over 200 patients; mostly ones with head and neck cancer, but some studies were conducted in prostate cancer patients, HIV-infected patients and patients with both HIV and HPV-induced cervical dysplasia (the precursor to cervical cancer) in the U.S., Canada, Europe and Israel. Co. owns a pre-clinical technology called L.E.A.P.S?. (Ligand Epitope Antigen Presentation System) used to develop Co.'s CEL-1000, which is being tested for avian flu, herpes simplex, malaria, viral encephalitis, smallpox, vaccinia treatment.
 Market CapDay's VolumeLast TradeChange
 $75M365,455$0.525-1.8692%
 
NASDAQ:CELGCelgene Corp
 Celgene is a biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory diseases through regulation of cellular, genomic and proteomic targets. As of Dec 31 2006, Co.'s lead products were REVLIMID , and THALOMID . Co. also sells bio-therapeutic products and services through its Cellular Therapeutics subsidiary. Also, at Dec 31 2006, Co.'s portfolio of drug candidates in its product pipeline included IMiDs compounds, which modulate the immune system and other biological targets through multiple mechanisms of action.
 Market CapDay's VolumeLast TradeChange
 -2,067,429$56.04-0.972%
 
NASDAQ:CERSCERUS
 Cerus is engaged in the development of medical systems, therapeutics and vaccines. Co.'s programs include those focused on systems to enhance the safety of blood products used for transfusion. The INTERCEPT Blood System, which is being developed in collaboration with subsidiaries of Baxter International Inc., is based on Co.'s proprietary Helinx technology for controlling biological replication. The INTERCEPT Blood System is designed to inactivate viruses, bacteria, other pathogens and potentially harmful white blood cells. The INTERCEP T Blood System for platelets is marketed in Europe by Baxter. Co. is also pursuing therapeutic cancer vaccine products, using its Listeria vaccine platform.
 Market CapDay's VolumeLast TradeChange
 -79,108$3.18-1.2423%
 
NYSE:CRLCharles River Laboratories International, Inc.
 Charles River Laboratories International is a global provider of services that advance the drug discovery and development process. Co. has two reporting segments: Research Models and Services is engaged in production and sale of research models, principally genetically and virally defined purpose-bred rats and mice; Co.'s Preclinical Services provides in vivo and in vitro studies, supportive laboratory services, and strategic preclinical consulting and program management to support new drug development. As of Dec 31 2006, Co. operated over 80 facilities, including its production and warehousing facilities, throughout 15 countries around the world.
 Market CapDay's VolumeLast TradeChange
 -727,785$30.76-0.646%
 
NASDAQ:CRXXCOMBINATORX
 CombinatoRx is a biopharmaceutical company in the field of synergistic combination pharmaceuticals, with a wide portfolio of product candidates in phase 2 clinical development. Going beyond traditional combinations, Co. creates product candidates with new mechanisms of action striking at the biological complexities of human disease. As of Dec 31 2006, Co. was developing a clinical portfolio of eight product candidates targeting multiple diseases including immuno-inflammatory diseases, chronic pain, topical dermatoses, metabolic disease and oncology as well as a broad preclinical pipeline including neurodegenerative and infectious disease programs.
 Market CapDay's VolumeLast TradeChange
 -581,755$1.61-2.4243%
 
OTC PK:CBTECommonwealth Biotechnologies, Inc.
 Commonwealth Biotechnologies is a fee-for-service contractor engagaed in offering integrated programs for life sciences investigations. Co. provides a range of services relating to the design, synthesis, purification, and analysis of peptides, proteins, and oligonucleotides, and creates assay and detection methods. In addition, through its Fairfax Identity Labs (FIL), Co. offers genetic identity testing, including paternity, forensic, and Convicted Offender Deoxyribonucleic Acid Index System (CODIS) analyses. Co. provides its services to the biotechnology industry, academic institutions, government agencies, and pharmaceutical companies.
 Market CapDay's VolumeLast TradeChange
 -0$0.390.0%
 
NASDAQ:CGENCOMPUGEN
 Compugen is are a drug and diagnostic discovery company. Co. develops platforms, discovery engines and related technologies that enable the discovery and analysis of genes and gene-based products, including mRNAs and proteins. These platforms include Co.'s LEADS computational biology platform, and its discovery engines, including Co.'s protein variant discovery engine and its diagnostic biomarkers discovery engines. Co. incorporates ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine. Co. provides computational technologies with biology to enhance drug discovery and development.
 Market CapDay's VolumeLast TradeChange
 -23,546$4.34-0.9133%
 
NYSE:CVDCovance, Inc.
 Covance is a drug development services company that provides a range of early stage and late stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries. Co. also provides laboratory testing services to the chemical, agrochemical and food industries. In addition, Co. maintains offices in more than 20 countries worldwide. Co. operates through two segments: early development services that include preclinical services and clinical pharmacology services; and late-stage development services that include central laboratory, clinical development, periapproval, cardiac safety services and market access services.
 Market CapDay's VolumeLast TradeChange
 -1,278,833$40.52-0.8807%
 
OTC PK:CTDHCTD Holdings, Inc.
 CTD Holdings is principally engaged in the sale and resale of cyclodextrins (CDs) and cyclodextrin complexes, and related products primarily to major chemical supply houses around the world, pharmaceutical companies, food companies for research and development, and to diagnostics companies. In addition, Co. provides consulting services related to cyclodextrin technology, research coordination, and the use of CD Infobase? , a comprehensive database of CD related information. Co.'s CD products include Trappsol , Aquaplex , AP?-Flavor product lines, and Garlessence . Co.'s products are principally acquired from outside the U.S., mainly from Japan and Hungary.
 Market CapDay's VolumeLast TradeChange
 -0$0.110.0%
 
NASDAQ:CRGNCURAGEN
 CuraGen is a biopharmaceutical development company that is engaged in the development of protein, monoclonal antibody, antibody-drug conjugate, and small molecule therapeutics for the treatment of cancer and cancer supportive care. Co. is mainly focused on advancing its pipeline of cancer treatments and cancer supportive care drug candidates through development and toward commercialization, including velafermin, belinostat (PXD101) and CR011-vcMMAE . In addition, Co. maintains a portfolio of earlier stage assets, including proteins, antibodies, and small molecules that represent potential treatments for cancer inflammatory diseases and diabetes.
 Market CapDay's VolumeLast TradeChange
 -0$1.440.0%
 
More Pages: Page: 1 (2) 3 4 5 6 7 8 9 10 11
More

The term Market Sector is used to describe a set of businesses that are buying and selling such similar goods and services that they are in direct competition with each other. Analysts divide the stock market itself into market sectors so that shares of companies that are in direct competition are listed alongside each other.

In the bond market it refers to the division of the market by the type of issuer. E.g. government, state, corporate, or utility.

Markets are split into sectors using the Global Industry Classification Standard.

Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts